At Journey Biosciences, we are dedicated to fundamentally improving diabetes care.
Our mission, at Journey Biosciences, is to provide people living with diabetes and their healthcare teams the diagnostic tools they need to assess their individual risk level for developing kidney complications associated with diabetes. We also deliver actionable insights for developing individualized care plans that minimize the progression of these complications.
Knowing the risks
We know that people with diabetes are at greater risk for developing and experiencing the devastating effects that come with diabetic kidney disease (DKD). We also understand that managing blood glucose levels so that they remain in-range helps people with diabetes stay more healthy overall. But glycemic management (measured using the A1C test) doesn’t reliably show us who will or won’t develop complications. Some people develop chronic kidney disease (CKD) despite maintaining “tight control.” While others with a history of higher glucose levels remain complication-free. Decades can pass before any sign of kidney damage shows itself.
Assessing the risks
The science behind our proactive diagnostic screening product is based on data collected as part of the most comprehensive longitudinal diabetes outcome studies done to-date (including the Natural History of Diabetic Nephropathy Study and Pima Indians studies and confirmed by the DCCT/EDIC and ACCORD Studies.) By matching blood biomarkers present with actual health outcomes documented in these studies, our Chief Scientific Officer Dr. Paul Beisswenger, MD and his research team uncovered strong correlations between the amount of advanced glycation end products (AGEs) in the blood of people with diabetes and their individual risk levels for developing kidney disease.
.png)
Journey answers the risk
Based on this research we created the NaviDKD® proactive diagnostic screening tool which delivers reliable, accurate readings of a person’s risk level for developing kidney complications from diabetes.
We at Journey Biosciences, a US-based biosciences company, are just getting started. We are working ahead to uncover what other complication risk levels can be revealed through proactive diagnostic analysis of blood biomarkers.
